· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Лечебное дело 2022 / N 1 Возможности стабильного контроля артериального давления в реальной клинической практике: фокус на применение фиксированной комбинации амлодипина и телмисартана О.А. Полякова, А.И. Кочетков, О.Д. Остроумова Список литературы 1. Lee J, Choi J, Yum Y, Joo HJ, Kim YH, An H, Kim EJ. Clinical effectiveness and safety of amlodipine/losartan-based single-pill combination therapy in patients with hypertension: findings from real-world, multicenter observational databases. The Journal of Clinical Hypertension (Greenwich, Conn.). 2021;23(11):1975-1983. DOI:10.1111/jch.14380 2. Rahimi K, Emdin CA, MacMahon S. The epidemiology of blood pressure and its worldwide management. Circulation Research. 2015;116(6):925-936. DOI:10.1161/CIRCRESAHA.116.304723 3. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957-967. DOI:10.1016/S0140-6736(15)01225-8 4. Li Y, Narisawa M, Huang Z, Meng X, Wang H, Jin X, Shen X, Cheng XW. Expanding role for single-pill combination drug therapy in the initial treatment of hypertension? The Journal of Clinical Hypertension (Greenwich, Conn.). 2021;23(11):1984-1986. DOI:10.1111/jch.14378 5. NCD Risk Factor Collaboration (NCD-RisC). Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. The Lancet. 2019;394(10199):639-651. DOI:10.1016/S0140-6736(19)31145-6 6. Geldsetzer P, Manne-Goehler J, Marcus ME, Ebert C, Zhumadilov Z, Wesseh CS, Tsabedze L, Supiyev A, Sturua L, Bahendeka SK, Sibai AM, Quesnel-Crooks S, Norov B, Mwangi KJ, Mwalim O, Wong-McClure R, Mayige MT, Martins JS, Lunet N, Labadarios D, Karki KB, Kagaruki GB, Jorgensen JMA, Hwalla NC, Houinato D, Houehanou C, Msaidié M, Guwatudde D, Gurung MS, Gathecha G, Dorobantu M, Damasceno A, Bovet P, Bicaba BW, Aryal KK, Andall-Brereton G, Agoudavi K, Stokes A, Davies, JI, Bärnighausen T, Atun R, Vollmer S, Jaacks LM. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1,1 million adults. The Lancet. 2019;394(10199):652-662. DOI:10.1016/S0140-6736(19)30955-9 7. Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension (Dallas, Tex.: 1979). 2021;77(2):692-705. DOI: 10.1161/HYPERTENSIONAHA.120.15781 8. Bruyn E, Nguyen L, Schutte AE, Murphy A, Perel P, Webster R. Implementing single-pill combination therapy for hypertension: a scoping review of key health system requirements in 30 low- and middle-income countries. Global Heart. 2022;17(1):6. DOI:10.5334/gh.1087 9. Министерство здравоохранения РФ. Российское кардиологическое общество. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Коды по МКБ 10: I10/ I11/ I12/ I13/ I15. Российский кардиологический журнал. 2020;25(3):149-218. [Ministry of Health of the Russian Federation. Russian Society of Cardiology. Arterial hypertension in adults. Clinical Guidelines 2020. ICD 10 codes: I10/I11/I12/I13/I15. Russian Journal of Cardiology. 2020;25(3):149-218. (In Russian)]. DOI:10.15829/1560-4071-2020-3-3786 10. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, Cesana G, Mancia G. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. Journal of Hypertension. 2008;26(4):819-824. DOI:10.1097/HJH.0b013e3282f4edd7 11. Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(4):e5641. DOI:10.1097/MD.0000000000005641 12. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296(21):2563-2571. DOI:10.1001/jama.296.21.joc60162 13. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip G, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021-3104. DOI:10.1093/eurheartj/ehy339 14. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension (Dallas, Tex.: 1979). 2020;75(6):1334-1357. DOI:10.1161/HYPERTENSIONAHA.120.15026 15. Kim SJ, Kwon OD, Cho B, Oh SW, Lee CM, Choi HC. Effects of combination drugs on antihypertensive medication adherence in a real-world setting: a Korean Nationwide Study. BMJ Open. 2019;9(6):e029862. DOI:10.1136/bmjopen-2019-029862 16. Weisser B, Predel HG, Gillessen A, Hacke C, Vor dem Esche J, Rippin G, Noetel A, Randerath O. Single pill regimen leads to better adherence and clinical outcome in daily practice in patients suffering from hypertension and/or dyslipidemia: results of a meta-analysis. High Blood Pressure & Cardiovascular Prevention. 2020;27(2):157-164. DOI:10.1007/s40292-020-00370-5 17. Tsioufis K, Kreutz R, Sykara G, van Vugt J, Hassan T. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. Journal of Hypertension. 2020;38(6):1016-1028. DOI:10.1097/HJH.0000000000002381 18. Nardin C, Rattazzi M, Pauletto P. Blood pressure variability and therapeutic implications in hypertension and cardiovascular diseases. High Blood Pressure & Cardiovascular Prevention. 2019;26(5):353-359. DOI:10.1007/s40292-019-00339-z 19. Mehlum MH, Liestøl K, Kjeldsen SE, Julius S, Hua TA, Rothwell PM, Mancia G, Parati G, Weber MA, Berge E. Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. European Heart Journal. 2018;39(24):2243-2251. DOI:10.1093/eurheartj/ehx760 20. Palatini P, Saladini F, Mos L, Fania C, Mazzer A, Cozzio S, Zanata G, Garavelli G, Biasion T, Spinella P, Vriz O, Casiglia E, Reboldi G. Short-term blood pressure variability outweighs average 24-h blood pressure in the prediction of cardiovascular events in hypertension of the young. Journal of Hypertension. 2019;37(7):1419-1426. DOI:10.1097/HJH.0000000000002074 21. Zhou TL, Henry RMA, Stehouwer CDA, van Sloten TT, Reesink KD, Kroon AA. Blood pressure variability, arterial stiffness, and arterial remodeling. Hypertension (Dallas, Tex.: 1979). 2018;72(4):1002-1010. DOI:10.1161/HYPERTENSIONAHA.118.11325 22. Kim JS, Park S, Yan P, Jeffers BW, Cerezo C. Effect of inter-individual blood pressure variability on the progression of atherosclerosis in carotid and coronary arteries: a post hoc analysis of the NORMALISE and PREVENT studies. European Heart Journal. Cardiovascular Pharmacotherapy. 2017;3(2):82-89. DOI:10.1093/ehjcvp/pvw019 23. Mustafa ER, Istrătoaie O, Mușetescu R. Blood pressure variability and left ventricular mass in hypertensive patients. Current Health Sciences Journal. 2016;42(1):47-50. DOI:10.12865/CHSJ.42.01.07 24. Wang X, Wang F, Chen M, Wang X, Zheng J, Qin A. Twenty-four-hour systolic blood pressure variability and renal function decline in elderly male hypertensive patients with well-controlled blood pressure. Clinical Interventions in Aging. 2018;13:533-540. DOI:10.2147/CIA.S161752 25. Filomena J, Riba-Llena I, Vinyoles E, Tovar JL, Mundet X, Castañé X, Vilar A, López-Rueda A, Jiménez-Baladó J, Cartanyà A, Montaner J, Delgado P, ISSYS Investigators. Short-term blood pressure variability relates to the presence of subclinical brain small vessel disease in primary hypertension. Hypertension (Dallas, Tex.: 1979). 2015;66(3):634-640: discussion 445. DOI:10.1161/HYPERTENSIONAHA.115.05440 26. Palatini P. Risk of developing foot ulcers in diabetes: contribution of high visit-to-visit blood pressure variability. Journal of Hypertension. 2018;36(11):2132-2134. DOI:10.1097/HJH.0000000000001815 27. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Pressure. Supplement. 2001;1:6-11. Accessed 2022 Apr 05. https://pubmed.ncbi.nlm.nih.gov/11333013/ 28. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. The Journal of International Medical Research. 2000;28(4):149-167. DOI:10.1177/147323000002800401 29. Takai S, Kirimura K, Jin D, Muramatsu M, Yoshikawa K, Mino Y, Miyazaki M. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertension Research. 2005;28(7):593-600. DOI:10.1291/hypres.28.593 30. Wienen W, Entzeroth M, van Meel JCA, Stangier J, Busch U, Ebner T, Schmid J, Lehmann H, Matzek K, Kempthorne-Rawson J, Gladigau V, Hauel NH. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovascular Drug Reviews. 2000;18(2):127-156. DOI:10.1111/j.1527-3466.2000.tb00039.x 31. Fogari R, Mugellini A, Zoppi A, Preti P, Destro M, Lazzari P, Derosa G. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics. 2012;17(1):34-43. DOI:10.1177/1074248410395018 32. Bernardo A, Malara M, Bertuccini L, De Nuccio C, Visentin S, Minghetti L. The antihypertensive drug telmisartan protects oligodendrocytes from cholesterol accumulation and promotes differentiation by a PPAR-γ-mediated mechanism. International Journal of Molecular Sciences. 2021;22(17):9434. DOI:10.3390/ijms22179434 33. Choi GJ, Kim HM, Kang H, Kim J. Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion. 2016;32(7):1303-1309. DOI:10.1185/03007995.2016.1171204 34. Wang Y, Qiao S, Han DW, Rong XR, Wang YX, Xue JJ, Yang J. Telmisartan improves insulin resistance: a meta-analysis. American Journal of Therapeutics. 2018;25(6):e642-e651. DOI:10.1097/MJT.0000000000000733 35. Takagi H, Yamamoto H, Iwata K, Goto SN, Umemoto T, ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials. International Journal of Cardiology. 2013;167(4):1443-1449. DOI:10.1016/j.ijcard.2012.04.058 36. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. The New England Journal of Medicine. 2008;358(15):1547-1559. DOI:10.1056/NEJMoa0801317 37. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. The Lancet. 2008;372(9644):1174-1183. DOI:10.1016/S0140-6736(08)61242-8 38. Fitchett D. Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vascular Health and Risk Management. 2009;5(1):21-29. Accessed 2022 Apr 05. https://pubmed.ncbi.nlm.nih.gov/19436659/ 39. Bulsara KG, Cassagnol M. Amlodipine. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 24, 2022. Accessed 2022 Apr 05. https://pubmed.ncbi.nlm.nih.gov/30137793/ 40. Fares H, DiNicolantonio JJ, O’Keefe JH, Lavie CJ. Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart. 2016;3(2):e000473. DOI:10.1136/openhrt-2016-000473 41. Toba H, Nakagawa Y, Miki S, Shimizu T, Yoshimura A, Inoue R, Asayama J, Kobara M, Nakata T. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertension Research. 2005;28(8):689-700. DOI:10.1291/hypres.28.689 42. Eickelberg O, Roth M, Block LH. Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection. International Journal of Cardiology. 1997;62(Suppl 2):S31-S37. DOI:10.1016/s0167-5273(97)00239-8 43. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet. 2005;366(9489):895-906. DOI:10.1016/S0140-6736(05)67185-1 44. Neldam S, Dahlöf B, Oigman W, Schumacher H. Early combination therapy with telmisartan plus amlodipine for rapid achievement of blood pressure goals. International Journal of Clinical Practice. 2013;67(9):843-852. DOI:10.1111/ijcp.12180 45. Littlejohn TW 3rd, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R, Oigman W; Study Investigators. Results of treatment with telmisartan-amlodipine in hypertensive patients. The Journal of Clinical Hypertension (Greenwich, Conn.). 2009;11(4):207-213. DOI:10.1111/j.1751-7176.2009.00098.x 46. Moen MD. Telmisartan/amlodipine: single-pill combination in hypertension. American Journal of Cardiovascular Drugs. 2010;10(6):401-412. DOI:10.2165/11204880-000000000-00000 47. Кочетков А.И., Эбзеева Е.Ю., Листратов А.И. Вариабельность артериального давления у пациентов с артериальной гипертонией: возможности коррекции в реальной клинической практике. Лечебное дело. 2021;3:30-38. [Kochetkov AI, Ebzeyeva EYu, Listratov AI. Blood pressure variability in patients with arterial hypertension: potential of correction in real clinical practice. Lechebnoye Delo. 2021;3:30-38. (In Russian)]. DOI:10.24412/2071-5315-2021-12357    [ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]